Gentium S.p.A. Announces NDA Submission for Defibrotide
VILLA GUARDIA (COMO), Italy, July 6, 2011 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for Defibrotide for the treatment of hepatic veno-occlusive disease (VOD) in adults and children undergoing hematopoietic stem-cell transplantation (HSCT).